Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nanobiosym Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing a diversified prosecution landscape. This distribution means the company must navigate different examination styles and technical standards simultaneously. Having 2 distinct art units involved suggests the portfolio covers multiple technical sub-sectors within the broader biotechnology field.
The busiest examiner for the company is PRIEST, AARON A, who is currently handling 1 busiest examiner pending office action. While this examiner is the most active, they only account for 1 of the 2 pending office actions in the portfolio. This split requires the company to manage separate prosecution tracks, each with its own examiner and art unit requirements. Practitioners must adapt their strategies to the specific feedback from the 2 distinct examiners to move the portfolio toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, AARON A | 1 | 61.3% | +25.7% |
| HERON, VELVET ELIZABETH | 1 | 47.4% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17141170 | Systems and Methods for Mobile Device Analysis of Nucleic Acids and Proteins | HERON, VELVET ELIZABETH | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17141170 | Systems and Methods for Mobile Device Analysis of Nucleic Acids and Proteins | HERON, VELVET ELIZABETH | 55d |
| 18138017 | SYSTEMS AND METHODS FOR MOBILE DEVICE ANALYSIS OF NUCLEIC ACIDS AND PROTEINS | PRIEST, AARON A | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18138017 | SYSTEMS AND METHODS FOR MOBILE DEVICE ANALYSIS OF NUCLEIC ACIDS AND PROTEINS | PRIEST, AARON A | 1681 | §102 | Non-Final OA | — | Pending | Apr 21, 2023 |
| 17141170 | Systems and Methods for Mobile Device Analysis of Nucleic Acids and Proteins | HERON, VELVET ELIZABETH | 1798 | §103§112 | Final Rejection | 55d | Pending | Jan 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial